Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Jul 2015 |
| Major Shareholder Announcement | 10 Jul 2015 |
| Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone | 9 Jul 2015 |
| Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL | 7 Jul 2015 |
| Articles of Association for Genmab A/S | 23 Jun 2015 |